Sunday, May 22, 2011

Test that tells you how long you'll live


DNA testing

The £400 test that tells you how long you'll live

DNA breakthrough heralds new medical era – and opens ethical Pandora's box
By Steve Connor, Science Editor
Monday, 16 May 2011
http://www.independent.co.uk/news/science/the-163400-test-that-tells-you-how-long-youll-live-2284639.html

A blood test that can show how fast someone is ageing – and offers the tantalising possibility of estimating how long they have left to live – is to go on sale to the general public in Britain later this year.
The controversial test measures vital structures on the tips of a person's chromosomes, called telomeres, which scientists believe are one of the most important and accurate indicators of the speed at which a person is ageing.
Scientists behind the €500 (£435) test said it will be possible to tell whether a person's "biological age", as measured by the length of their telomeres, is older or younger than their actual chronological age.
Medical researchers believe that telomere testing will become widespread within the next five or 10 years, but there are already some scientists who question its value and whether there should be stronger ethical controls over its wider use. In addition to concerns about how people will react to a test for how "old" they really are, some scientists are worried that telomere testing may be hijacked by unscrupulous organisations trying to peddle unproven anti-ageing remedies and other fake elixirs of life.
The results of the tests might also be of interest to companies offering life-insurance policies or medical cover that depend on a person's lifetime risk of falling seriously ill or dying prematurely. However, there is a growing body of scientific opinion that says testing the length of a person's telomeres could provide vital insights into the risk of dying prematurely from a range of age-related disorders, from cardiovascular disease to Alzheimer's and cancer. "We know that people who are born with shorter telomeres than normal also have a shorter lifespan. We know that shorter telomeres can cause a shorter lifespan," said Maria Blasco of the Spanish National Cancer Research Centre in Madrid, who is the inventor of the new commercial telomere test. "But we don't know whether longer telomeres are going to give you a longer lifespan. That's not really known in humans," she added.
"What is new about this test is that it is very precise. We can detect very small differences in telomere length and it is a very simple and fast technique where many samples can be analysed at the same time. Most importantly, we are able to determine the presence of dangerous telomeres – those that are very short."
Dr Blasco's company, Life Length, is in talks with medical diagnostic companies across Europe, including the UK, to market the test and collect blood samples for analysis in Spain. A deal with a company operating in Britain is likely within a year, she said.
"We need to have a clinical company to send us the blood [samples]. We are in contact with several groups in the UK who are interested," Dr Blasco said.
Life Length is anticipating hundreds of requests from people wanting to have their telomeres tested and is expecting demand from thousands more once the company is able to bring down the cost of the test as public demand increases.
Although Life Length is not the only company selling telomere tests, it is the only one gearing up for over-the-counter sales to the public and the only company with an accurate-enough test to be of practical use, said Professor Jerry Shay of the University of Texas Southwestern Medical Centre in Dallas.
"This test devised by Blasco is so accurate that it is likely to provide more useful information than some of the other tests out there right now," said Professor Shay, who is a scientific consultant for Life Length. "What's important in ageing is the shortest telomeres. What makes cells stop growing is the shortest telomeres, not the average telomere length, which is what other tests look at.
"Everyone talks about the chronological age, but there is also a biological age, and telomere length is actually a pretty good representation of your biological age. Telomeres are important – there is no question of that," he said.
Asked why the general public would be interested in taking a telomere test, Dr Shay said: "I think people are just basically curious about their own mortality. If you ask people what they worry about, most people would say they are worried about dying."
He added: "People might say 'If I know I'm going to die in 10 years I'll spend all my money now', or 'If I'm going to live for 40 more years I'll be more conservative in my lifestyle'. The worrying thing is that if this information ever got to a point where it is believable, insurance companies would start requiring it in terms of insuring people.
"If you smoke or you're obese your insurance rates are higher, and if you have short telomeres your insurance rates might be higher too."
Scientists do not yet believe they can narrow down the test prediction to calculate the exact number of months and years a person has yet to live, but several studies have indicated that individuals with telomeres that shorter than normal are likely to die younger than those with longer telomeres. Telomere research is considered to be one of the most exciting areas in biomedical science and last year the Nobel Prize in medicine was shared between three scientists who are pioneers in the field.
Interestingly, one of the Nobel laureates, Elizabeth Blackburn of the University of California San Francisco, is an enthusiastic proponent of telomere testing while another of the prize-winners, Carol Greider of Harvard Medical School, is more sceptical of its benefits.
"Do I think it's useful to have a bunch of companies offering to measure telomere length so people can find out how old they are? No," Dr Greider recently told the journal Science.
Dr Blasco, a former post-doctoral student in Dr Greider's laboratory, is more certain of the benefits. "It will be useful for you to know your biological age and maybe to change your lifestyle habits if you find you have short telomeres," she said.
Telomeres: a short history
* 2003 Scientists studying 20-year-old blood samples from 143 people show that telomere length is good indicator of whether someone is likely to live for 15 years or more once they reach 60.
* 2004 Women living with stress of having a sick child are found to have shorter telomeres. Other research suggests that meditation or other forms of stress reduction may lengthen telomeres.
* 2007 Study of men in Scotland shows those with the longest telomeres were half as likely to develop heart disease than those with shorter telomeres. Telomere length was as good as cholesterol levels at predicting the risk of developing cardiovascular disease.
* 2009 Short telomeres linked with inherited bone marrow disease.
* 2010 GM mice with no telomerase, an enzyme that elongates telomeres in some cells, age prematurely compared to normal mice. The ageing effects were reversed after injections of telomerase.
* 2011 Study of civil servants in the UK shows that those with few educational qualifications have shorter telomeres than those with higher educational qualifications. People with poor backgrounds are known to age faster and suffer more age-related diseases.

Cancer Cure?

http://hubpages.com/hub/Scientists_cure_cancer__but_no_one_takes_notice



Canadian researchers find a simple cure for cancer, but major pharmaceutical companies are not interested.

Researchers at the University of Alberta, in Edmonton, Canada have cured cancer last week, yet there is a little ripple in the news or in TV. It is a simple technique using very basic drug. The method employs dichloroacetate, which is currently used to treat metabolic disorders. So, there is no concern of side effects or about their long term effects.

This drug doesn’t require a patent, so anyone can employ it widely and cheaply compared to the costly cancer drugs produced by major pharmaceutical companies.

Canadian scientists tested this dichloroacetate (DCA) on human’s cells; it killed lung, breast and brain cancer cells and left the healthy cells alone. It was tested on Rats inflicted with severe tumors; their cells shrank when they were fed with water supplemented with DCA. The drug is widely available and the technique is easy to use, why the major drug companies are not involved? Or the Media interested in this find?

In human bodies there is a natural cancer fighting human cell, the mitochondria, but they need to be triggered to be effective. Scientists used to think that these mitochondria cells were damaged and thus ineffective against cancer. So they used to focus on glycolysis, which is less effective in curing cancer and more wasteful. The drug manufacturers focused on this glycolysis method to fight cancer. This DCA on the other hand doesn’t rely on glycolysis instead on mitochondria; it triggers the mitochondria which in turn fights the cancer cells.

The side effect of this is it also reactivates a process called apoptosis. You see, mitochondria contain an all-too-important self-destruct button that can't be pressed in cancer cells. Without it, tumors grow larger as cells refuse to be extinguished. Fully functioning mitochondria, thanks to DCA, can once again die.

With glycolysis turned off, the body produces less lactic acid, so the bad tissue around cancer cells doesn't break down and seed new tumors.

Pharmaceutical companies are not investing in this research because DCA method cannot be patented, without a patent they can’t make money, like they are doing now with their AIDS Patent. Since the pharmaceutical companies won’t develop this, the article says other independent laboratories should start producing this drug and do more research to confirm all the above findings and produce drugs. All the groundwork can be done in collaboration with the Universities, who will be glad to assist in such research and can develop an effective drug for curing cancer.

This article wants to raise awareness for this study, hope some independent companies and small startup will pick up this idea and produce these drugs, because the big companies won’t touch it for a long time.

Monday, January 24, 2011

Exercise: In Women, Weight Training for a Sharper Mind

http://www.nytimes.com/2010/01/26/health/research/26exer.html?_r=1
January 26, 2010
VITAL SIGNS


By RONI CARYN RABIN
Older women who did an hour or two of strength training exercises each week had improved cognitive function a year later, scoring higher on tests of the brain processes responsible for planning and executing tasks, a new study has found.

Researchers in British Columbia randomly assigned 155 women ages 65 to 75 either to strength training with dumbbells and weight machines once or twice a week, or to a comparison group doing balance and toning exercises.

A year later, the women who did strength training had improved their performance on tests of so-called executive function by 10.9 percent to 12.6 percent, while those assigned to balance and toning exercises experienced a slight deterioration — 0.5 percent. The improvements in the strength training group included an enhanced ability to make decisions, resolve conflicts and focus on subjects without being distracted by competing stimuli.

Older women are generally less likely than others to do strength training, even though it can promote bone health and counteract muscle loss, said Teresa Liu-Ambrose, a researcher at the Center for Hip Health and Mobility at Vancouver General Hospital and the lead author of the paper, which appears in the Jan. 25 issue of Archives of Internal Medicine.

Blocking Rogue Gene Could Stop Spread of Cancer, New Research Suggests

http://www.sciencedaily.com/releases/2011/01/110124073903.htm

ScienceDaily (Jan. 24, 2011) — Scientists at the University of East Anglia (UEA) have discovered a rogue gene involved in the spread of cancer in the body. By blocking the gene, they believe, cancer could be stopped in its tracks.

Published in the journal Oncogene, the discovery is a breakthrough in our understanding of how cancer spreads. It is hoped the research will lead to new drugs that halt the critical late stage of the disease when cancer cells spread to other parts of the body.

The culprit gene -- known as WWP2 -- is an enzymic bonding agent found inside cancer cells. It attacks and breaks down a natural inhibitor in the body which normally prevents cancer cells spreading. The UEA team found that by blocking WWP2, levels of the natural inhibitor are boosted and the cancer cells remain dormant.If a drug was developed that deactivated WWP2, conventional therapies and surgery could be used on primary tumours, with no risk of the disease taking hold elsewhere.

Lead author Andrew Chantry, of UEA's School of Biological Sciences, said the discovery could lead to the development of a new generation of drugs within the next decade that could be used to stop the aggressive spread of most forms of the disease, including breast, brain, colon and skin cancer.
"The late-stages of cancer involve a process known as metastasis -- a critical phase in the progression of the disease that cannot currently be treated or prevented," said Dr Chantry.
"The challenge now is to identify a potent drug that will get inside cancer cells and destroy the activity of the rogue gene. This is a difficult but not impossible task, made easier by the deeper understanding of the biological processes revealed in this study."
The research was funded by UK-based charity the Association of International Cancer Research (AICR), with additional support from the Big C Charity and the British Skin Foundation.
Dr Mark Matfield, scientific co-ordinator of AICR, said: "This is a very exciting new discovery and a perfect example of the way that basic research into cancer can open up ways to develop new ways to treat cancer."
The initial discovery was made while researchers were studying a group of natural cancer cell inhibitors called 'Smads'.
Dr Surinder Soond, who spearheaded the experimental work in the laboratory, said: "This is a very novel and exciting approach to treating cancer and the spread of tumours which holds great potential."

Tuesday, December 7, 2010

Daily Aspirin Cuts Many Cancer Risks

http://www.foxnews.com/health/2010/12/07/study-daily-aspirin-cuts-cancer-risks/#ixzz17RlnbXiH

Published December 07, 2010 | Reuters


Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.
The findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.

In a study of eight trials involving 25,570 patients, researchers found that cancer deaths among those who took aspirin in doses as low as 75 milligrams a day were 21 percent lower during the studies and 34 percent lower after five years.
Aspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.

Peter Rothwell of Britain's Oxford University said that while taking aspirin carries a small risk of stomach bleeding, that risk was beginning to be "drowned out" by its benefits in reducing the risk of cancer and the risk of heart attacks.
"Previous guidelines have rightly cautioned that in healthy middle-aged people the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks, but the reductions in deaths due to several common cancers will now alter this balance for many people," he said.

His suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.
"REMARKABLE DRUG"

Aspirin, originally developed by Bayer, is a cheap over-the-counter drug used for pain and to reduce fever.
Previous studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.

Alastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists' understanding of how to prevent cancer.
"It is further proof that aspirin is, by a long way, the most amazing drug in the world," he said.

In Rothwell's study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for esophageal cancer in those taking aspirin.

Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.
The researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.

Peter Elwood, an expert on aspirin from Cardiff University's medical school who was not involved in this study, described aspirin as "a remarkable drug". "This risk of a bleed is so small compared to the benefits," he told reporters. "Yes, okay, it's a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial."

Friday, December 3, 2010

Mercury poisoning makes male birds homosexual


01 December 2010 by Michael Marshall


Low levels of mercury in the diet of male white ibises cause the birds to mate with each other rather than with females. As a result many of the females can't breed, and fewer chicks are produced.

It's the first time a pollutant has been found to change an animal's sexual preference. Many chemicals can "feminise" males or reduce fertility, but males affected in these ways still prefer females.

Mercury is extremely toxic, particularly in the form of methylmercury, which reduces breeding in wild birds by disrupting their parenting behaviours. To find out if it also affected mating, Peter Frederick of the University of Florida in Gainesville and Nilmini Jayasena of the University of Peradeniya, Sri Lanka, captured 160 young white ibises from south Florida. They gave them food laced with methylmercury and monitored them closely.

The birds were split into four groups. One group ate food with 0.3 parts per million methylmercury, which most US states would regard as too high for human consumption. A second group got 0.1 ppm, and the third 0.05 ppm, a low dose that wild birds would be exposed to frequently. The fourth group received none.

Poisoned

All three dosed groups had significantly more homosexual males than the control group. Male-male pairs courted, built nests together and paired off for several weeks. Higher doses increased the effect, with 55 per cent of males in the 0.3 ppm group affected. Male-male matings were responsible for 81 per cent of unproductive nests in the dosed groups.

Meanwhile the heterosexual pairs courted less and were bad at parenting – patterns of behaviour that were both already known to be caused by methylmercury poisoning. The combined effects of male-male pairing and poor performance by male-female pairs could be severe. "In the worst-case scenario, the production of young would fall by 50 per cent," says Frederick.

Looking for effects on courtship and mating is novel, says Tony Scheuhammer of Environment Canada's National Wildlife Research Center in Ottawa, Ontario. "People normally study pairs that have already mated to see how good they are at parenting," he says.

Other birds would probably be similarly affected, though both Frederick and Scheuhammer say it's far from clear whether other animal groups would be. In particular, there's no evidence for increased homosexuality in humans resulting from mercury poisoning, despite several long-term studies. "If the effect was as strong in humans as in the ibises, they'd have found it," Frederick says.

Journal reference: Proceedings of the Royal Society B, DOI: 10.1098/rspb.2010.2189

Spray-On Stem Cells Speed Healing Process For Burn Victims

http://www.care2.com/causes/health-policy/blog/spray-on-stem-cells-accelerate-healing-for-burn-victims/




An experimental stem cell treatment is helping to speed up the healing process for burn victims, according to researchers at the University of Utah.

We've all heard of spray-on tans, and (ahem) clothing, but now the same principle of instant-application is being used to provide a speedy recovery process for those that are suffering from serious burns.

In clinical trials, surgeons Amit Patel and Amalia Cochran are testing "a concentrate of [the patient's own] platelets and progenitor cells with calcium and thrombin to create a Jello-like substance accelerates the healing process".

Popular Science reports that "in tests, the spray has proven effective in the treatment of small burns and seems to improve the likelihood that a skin graft will take, which could carry positive implications for the application of this technology to other types of transplants."


A similar treatment, called ReCell, is already being used in Australia, Europe and China and made headlines when it was used to treat of victims of a 2002 bombing in Bali.

So far, the spray-on treatment is only being used on patients with small burns, but the researchers hope that someday they maybe able to scale up the process to treat those who sustain burns on large areas of their body, like military personnel or people that have been caught in a house fire.